Literature DB >> 33572534

Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.

Daniel Aghaie Madsen1, Sissel Ida Schmidt1, Morten Blaabjerg1,2,3,4, Morten Meyer1,2,3,4.   

Abstract

Parkin and α-synuclein are two key proteins involved in the pathophysiology of Parkinson's disease (PD). Neurotoxic alterations of α-synuclein that lead to the formation of toxic oligomers and fibrils contribute to PD through synaptic dysfunction, mitochondrial impairment, defective endoplasmic reticulum and Golgi function, and nuclear dysfunction. In half of the cases, the recessively inherited early-onset PD is caused by loss of function mutations in the PARK2 gene that encodes the E3-ubiquitin ligase, parkin. Parkin is involved in the clearance of misfolded and aggregated proteins by the ubiquitin-proteasome system and regulates mitophagy and mitochondrial biogenesis. PARK2-related PD is generally thought not to be associated with Lewy body formation although it is a neuropathological hallmark of PD. In this review article, we provide an overview of post-mortem neuropathological examinations of PARK2 patients and present the current knowledge of a functional interaction between parkin and α-synuclein in the regulation of protein aggregates including Lewy bodies. Furthermore, we describe prevailing hypotheses about the formation of intracellular micro-aggregates (synuclein inclusions) that might be more likely than Lewy bodies to occur in PARK2-related PD. This information may inform future studies aiming to unveil primary signaling processes involved in PD and related neurodegenerative disorders.

Entities:  

Keywords:  Lewy bodies; PARK2; familial Parkinson’s disease; parkin; α-synuclein

Year:  2021        PMID: 33572534      PMCID: PMC7911026          DOI: 10.3390/cells10020283

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  239 in total

Review 1.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

2.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.

Authors:  Cheng Wang; Han Seok Ko; Bobby Thomas; Fai Tsang; Katherine C M Chew; Shiam-Peng Tay; Michelle W L Ho; Tit-Meng Lim; Tuck-Wah Soong; Olga Pletnikova; Juan Troncoso; Valina L Dawson; Ted M Dawson; Kah-Leong Lim
Journal:  Hum Mol Genet       Date:  2005-11-08       Impact factor: 6.150

Review 4.  Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?

Authors:  Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Neurobiol Aging       Date:  2005-10-06       Impact factor: 4.673

Review 5.  Mitochondrial dynamics and Parkinson's disease: focus on parkin.

Authors:  Kah-Leong Lim; Xiao-Hui Ng; Lim Gui-Yin Grace; Tso-Pang Yao
Journal:  Antioxid Redox Signal       Date:  2011-07-22       Impact factor: 8.401

6.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

7.  Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.

Authors:  Annika F M Haywood; Brian E Staveley
Journal:  Genome       Date:  2006-05       Impact factor: 2.166

Review 8.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

9.  Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.

Authors:  Steven R Danielson; Jason M Held; Birgit Schilling; May Oo; Bradford W Gibson; Julie K Andersen
Journal:  Anal Chem       Date:  2009-09-15       Impact factor: 6.986

10.  Exosomal cell-to-cell transmission of alpha synuclein oligomers.

Authors:  Karin M Danzer; Lisa R Kranich; Wolfgang P Ruf; Ozge Cagsal-Getkin; Ashley R Winslow; Liya Zhu; Charles R Vanderburg; Pamela J McLean
Journal:  Mol Neurodegener       Date:  2012-08-24       Impact factor: 14.195

View more
  6 in total

Review 1.  Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.

Authors:  Tapan Behl; Sachin Kumar; Ziyad M Althafar; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Shivam Yadav; Saurabh Bhatia; Ahmed Al-Harrasi; Yosif Almoshari; Mohannad A Almikhlafi; Simona Bungau
Journal:  Mol Neurobiol       Date:  2022-05-03       Impact factor: 5.590

2.  Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways.

Authors:  Jiahui Shao; Xuan Liu; Mengjia Lian; Youbing Mao
Journal:  Neurotox Res       Date:  2022-09-12       Impact factor: 3.978

Review 3.  The Promise of the Zebrafish Model for Parkinson's Disease: Today's Science and Tomorrow's Treatment.

Authors:  Khairiah Razali; Noratikah Othman; Mohd Hamzah Mohd Nasir; Abd Almonem Doolaanea; Jaya Kumar; Wisam Nabeel Ibrahim; Norlinah Mohamed Ibrahim; Wael M Y Mohamed
Journal:  Front Genet       Date:  2021-04-15       Impact factor: 4.599

Review 4.  Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.

Authors:  Milton H Werner; C Warren Olanow
Journal:  Mov Disord       Date:  2021-11-23       Impact factor: 9.698

5.  Nilotinib in Parkinson's disease: A systematic review and meta-analysis.

Authors:  Xiaolu Xie; Ping Yuan; Liqiu Kou; Xiu Chen; Jun Li; Yaling Li
Journal:  Front Aging Neurosci       Date:  2022-09-29       Impact factor: 5.702

Review 6.  Role of USP13 in physiology and diseases.

Authors:  Qian Wang; Zhenzhen Sun; Weiwei Xia; Le Sun; Yang Du; Yue Zhang; Zhanjun Jia
Journal:  Front Mol Biosci       Date:  2022-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.